Australian Clinical Labs Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Melinda McGrath
Chief executive officer
AU$1.6m
Total compensation
| CEO salary percentage | 55.9% |
| CEO tenure | 4yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5.5yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Sep 03
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Sep 02We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$2m | AU$873k | AU$24m |
| Mar 31 2024 | n/a | n/a | AU$20m |
| Dec 31 2023 | n/a | n/a | AU$15m |
| Sep 30 2023 | n/a | n/a | AU$26m |
| Jun 30 2023 | AU$1m | AU$873k | AU$36m |
| Mar 31 2023 | n/a | n/a | AU$55m |
| Dec 31 2022 | n/a | n/a | AU$73m |
| Sep 30 2022 | n/a | n/a | AU$126m |
| Jun 30 2022 | AU$2m | AU$873k | AU$178m |
| Mar 31 2022 | n/a | n/a | AU$156m |
| Dec 31 2021 | n/a | n/a | AU$134m |
| Sep 30 2021 | n/a | n/a | AU$97m |
| Jun 30 2021 | AU$2m | AU$875k | AU$60m |
| Mar 31 2021 | n/a | n/a | AU$79m |
| Dec 31 2020 | n/a | n/a | AU$98m |
| Sep 30 2020 | n/a | n/a | AU$70m |
| Jun 30 2020 | AU$2m | AU$852k | AU$41m |
Compensation vs Market: Melinda's total compensation ($USD975.88K) is about average for companies of similar size in the Australian market ($USD888.46K).
Compensation vs Earnings: Melinda's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Melinda McGrath
4yrs
Tenure
AU$1,560,335
Compensation
Ms. Melinda McGrath is Chief Executive Officer and Executive Director at Australian Clinical Labs Limited since December 19, 2020. She served as Chief Executive Officer and Executive Director at Clinical L...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4yrs | AU$1.56m | 1.09% A$ 7.5m | |
| Chief Executive Officer of Victoria | 1.9yrs | AU$37.27k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 8.9yrs | no data | 0% A$ 0 | |
| Chief Information Officer | 9.9yrs | no data | no data | |
| National Marketing Director | no data | no data | no data | |
| National Medical Director & Chief Pathologist | 15.9yrs | no data | 0% A$ 0 | |
| Chief Executive Officer of New South Wales & Australian Capital Territory | 13.9yrs | no data | no data | |
| Chief Executive Officer of WA/SA/NT | 6.9yrs | no data | no data | |
| Company Secretary | 3.7yrs | no data | no data | |
| Chief Executive Officer of ACL Commercial Pathology | 1.9yrs | no data | no data |
5.5yrs
Average Tenure
Experienced Management: ACL's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4yrs | AU$1.56m | 1.09% A$ 7.5m | |
| Non-Executive Chairman | 1.3yrs | AU$152.73k | 0.14% A$ 964.9k | |
| Independent Non-Executive Director | 1.3yrs | AU$111.74k | 0.010% A$ 68.8k | |
| Independent Non-Executive Director | 3.7yrs | AU$131.18k | 0.0025% A$ 17.2k | |
| Independent Non-Executive Director | 3.7yrs | AU$136.23k | 0.024% A$ 163.4k |
3.7yrs
Average Tenure
61yo
Average Age
Experienced Board: ACL's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Australian Clinical Labs Limited is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Lyanne Harrison | BofA Global Research |
| Mathieu Chevrier | Citigroup Inc |